NCT00793000 is a Phase 1 clinical trial of PF-04287881 in Respiratory Tract Infections, sponsored by Pfizer.

Who is sponsoring NCT00793000?

NCT00793000 is sponsored by Pfizer.

What drugs are being tested in NCT00793000?

Interventions in NCT00793000: PF-04287881, Placebo, PF-04287881, Placebo, PF-04287881, Placebo, PF-04287881, Placebo, PF-04287881, Placebo, PF-04287881, Placebo, PF-04287881, Placebo, PF-04287881, Placebo, PF-04287881, Placebo, PF-04287881, Placebo.

What condition does NCT00793000 study?

NCT00793000 studies Respiratory Tract Infections.

Is NCT00793000 still recruiting?

NCT00793000 is currently completed. Last updated 3 May 2011.

Last reviewed 2011-05-03 · How we verify

NCT00793000

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 1 Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04287881 After First Time Administration Of Ascending Single Oral Doses To Healthy Adult Subjects

Completed Phase 1 Last updated 3 May 2011

What this trial tests

Phase 1 trial testing PF-04287881 in Respiratory Tract Infections in 80 participants. Completed in 1 December 2009.

Timeline

1 November 2008

Primary endpoint
1 December 2009

1 December 2009

Quick facts

Lead sponsor	Pfizer
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Enrollment	80
Start date	1 November 2008
Primary completion	1 December 2009
Estimated completion	1 December 2009
Sites	1 location across United States

Drugs / interventions tested

PF-04287881 — full drug profile →
Placebo
PF-04287881 — full drug profile →
Placebo
PF-04287881 — full drug profile →
Placebo
PF-04287881 — full drug profile →
Placebo
PF-04287881 — full drug profile →
Placebo
PF-04287881 — full drug profile →
Placebo
PF-04287881 — full drug profile →
Placebo
PF-04287881 — full drug profile →
Placebo
PF-04287881 — full drug profile →
Placebo
PF-04287881 — full drug profile →
Placebo

Conditions studied

Respiratory Tract Infections — all drugs for Respiratory Tract Infections →

Sponsor

Pfizer — full company profile →

Who can join

Adults 18 to 55, any sex, with Respiratory Tract Infections. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Evaluation of safety and tolerability of PF-04287881 after single oral dose.
Time frame: Daily up to discharge, follow-up 7-10 days after dosing

Sponsor's own description

The purpose of this study is to determine the safety, tolerability and pharmacokinetics of PF-04287881 after a single oral dose in healthy adult volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Respiratory Tract Infections

Currently open trials in the same condition.

NCT07207291 — Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers · Phase 1 · recruiting
NCT06715306 — Intravenous Versus Oral Treatment of the Main Acute Infections · NA · recruiting
NCT06472219 — PREDICATE Trial For Respiratory Tract Infections · Phase 3 · recruiting
NCT05914324 — Outpatient Pediatric Pulse Oximeters in Africa · NA · recruiting
NCT06579170 — Burden of Recreational Water Illness Due to Exposure to Cyanobacteria and Their Toxins in Freshwater Beaches in Canada · active not recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00793000 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 3 May 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00793000.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing